1 unchanged sentence
Market Information
−Removed: Our common stock is traded on the Nasdaq Global Select Market under the symbol “RCKT”.
+Added: Our common stock is traded on the Nasdaq Global Select under the symbol “RCKT”.
Effective December 24, 2018, we began trading on the Nasdaq Biotechnology Index (Nasdaq:
−Removed: As of March 2, 2020, there were 15 stockholders of record, which excludes stockholders whose shares were held in nominee or street name by brokers.
+Added: On February 22, 2021, the last reported sale price for our common stock on the Nasdaq Global Market was $55.73 per share.
+Added: Stock Performance Graph
+Added: The graph set forth below compares the cumulative total stockholder return on our common stock between January 1, 2016 and December 31, 2020 with the cumulative total return of (a) the Nasdaq Biotechnology Index and (b) the Nasdaq Composite Index, over the same period.
+Added: This graph assumes the investment of $100 on January 1, 2016 of our common stock, the Nasdaq Biotechnology Index and the Nasdaq Composite Index and assumes the reinvestment of dividends, if any.
+Added: The comparisons shown in the graph below are based upon historical data.
+Added: We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.
+Added: As of February 22, 2021, there were 13 stockholders of record, which excludes stockholders whose shares were held in nominee or street name by brokers.
+Added: We completed a reverse merger which closed on January 4, 2018.
+Added: The stock performance information prior to January 4, 2018, represents the share price of our predecessor company Inotek Pharmaceuticals Corporation prior to the reverse merger as adjusted for a 4 for 1 reverse split completed upon the reverse merger.
Dividend Policy
We have never declared or paid any cash dividends on our capital stock.
−Removed: We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of
−Removed: our business and we do not anticipate paying any cash dividends in the foreseeable future.
+Added: We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future.
Any future determination to pay cash dividends will be made at the discretion of our board of directors.
−Removed: In addition, the terms of our outstanding
−Removed: indebtedness restrict our ability to pay cash dividends, and any future indebtedness that we may incur could preclude us from paying cash dividends.
+Added: In addition, the terms of our outstanding indebtedness restrict our ability to pay cash dividends, and any future indebtedness that we may incur could preclude us from paying cash dividends.
Investors should not purchase our common stock with the expectation of receiving cash dividends.
1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: There were no repurchases of our common stock during the quarter ended December 31, 2019.
+Added: There were no repurchases of our common stock during the year ended December 31, 2020.
Selected Financial Data
−Removed: Non-applicable.
+Added: For the Years Ended December 31,
+Added: Operating expenses:
+Added: Research and development
+Added: General and administrative
+Added: Total operating expenses
+Added: Loss from operations
+Added: Research and development incentives
+Added: Interest expense
+Added: Interest and other income net
+Added: (Amortization of premium) accretion of discount on investments - net
+Added: Net loss per share attributable to common stockholders - basic and diluted
+Added: Weighted-average common shares outstanding - basic and diluted
+Added: For the Years Ended December 31,
+Added: Cash, cash equivalents and investments
+Added: Total liabilities
+Added: Accumulated deficit
+Added: Total stockholders’ equity
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.